Jessica S Galo1, Pavandeep Mehat2, Sharan K Rai3, Antonio Avina-Zubieta4, Mary A De Vera2. 1. University of British Columbia Faculty of Pharmaceutical Sciences, Vancouver, British Columbia, Canada. 2. University of British Columbia Faculty of Pharmaceutical Sciences, Vancouver, British Columbia, Canada Arthritis Research Canada, Richmond, British Columbia, Canada. 3. Arthritis Research Canada, Richmond, British Columbia, Canada Department of Experimental Medicine, University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada. 4. Arthritis Research Canada, Richmond, British Columbia, Canada Department of Experimental Medicine, University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada Division of Rheumatology, University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada.
Abstract
OBJECTIVES: Consistent reports of suboptimal treatment adherence among patients with inflammatory arthritis underscore the importance of understanding how adherence can be promoted and supported. Our objectives were to identify and classify adherence interventions; and assess the evidence on the effects of adherence interventions on outcomes of patients with rheumatic diseases. METHODS: We conducted a mapped search of Medline, Embase and International Pharmaceutical Abstract databases to identify studies meeting inclusion criteria of: (1) patient population with inflammatory arthritis; (2) evaluation of an intervention or programme targeting medication adherence directly or indirectly; (3) reporting of one or more measures of medication adherence and disease outcome; (4) publication in English, French or Spanish. For our first objective, we applied a structured framework to classify interventions according target (patient vs provider), focus (educational vs behavioural vs affective), implementation (generalised vs tailored), complexity (single vs multifaceted) and provider. For the second objective, we appraised the evidence of effects of interventions on adherence and disease outcomes. RESULTS: We identified 23 studies reporting adherence interventions that directly or indirectly addressed treatment adherence in rheumatic diseases and further appraised included RCTs. Interventions that were shown to impact adherence outcomes were generally interventions directed at adherence, tailored to patients and delivered by a healthcare provider. For interventions that were not shown to have impacts, reasons may be those related to the intervention itself, patient characteristics or study methodology. CONCLUSIONS: Our systematic review shows limited research on adherence interventions in rheumatic diseases with inconsistent impacts on adherence or disease outcome. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
OBJECTIVES: Consistent reports of suboptimal treatment adherence among patients with inflammatory arthritis underscore the importance of understanding how adherence can be promoted and supported. Our objectives were to identify and classify adherence interventions; and assess the evidence on the effects of adherence interventions on outcomes of patients with rheumatic diseases. METHODS: We conducted a mapped search of Medline, Embase and International Pharmaceutical Abstract databases to identify studies meeting inclusion criteria of: (1) patient population with inflammatory arthritis; (2) evaluation of an intervention or programme targeting medication adherence directly or indirectly; (3) reporting of one or more measures of medication adherence and disease outcome; (4) publication in English, French or Spanish. For our first objective, we applied a structured framework to classify interventions according target (patient vs provider), focus (educational vs behavioural vs affective), implementation (generalised vs tailored), complexity (single vs multifaceted) and provider. For the second objective, we appraised the evidence of effects of interventions on adherence and disease outcomes. RESULTS: We identified 23 studies reporting adherence interventions that directly or indirectly addressed treatment adherence in rheumatic diseases and further appraised included RCTs. Interventions that were shown to impact adherence outcomes were generally interventions directed at adherence, tailored to patients and delivered by a healthcare provider. For interventions that were not shown to have impacts, reasons may be those related to the intervention itself, patient characteristics or study methodology. CONCLUSIONS: Our systematic review shows limited research on adherence interventions in rheumatic diseases with inconsistent impacts on adherence or disease outcome. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Kai Sun; Amanda M Eudy; Jennifer L Rogers; Lisa G Criscione-Schreiber; Rebecca E Sadun; Jayanth Doss; Mithu Maheswaranathan; Ann Cameron Barr; Lena Eder; Amy L Corneli; Hayden B Bosworth; Megan E B Clowse Journal: Arthritis Care Res (Hoboken) Date: 2021-11-05 Impact factor: 5.178
Authors: Kai Sun; Amy L Corneli; Carrie Dombeck; Teresa Swezey; Jennifer L Rogers; Lisa G Criscione-Schreiber; Rebecca E Sadun; Amanda M Eudy; Jayanth Doss; Hayden B Bosworth; Megan E B Clowse Journal: Arthritis Care Res (Hoboken) Date: 2022-06-01 Impact factor: 5.178
Authors: Marieke Voshaar; Johanna Vriezekolk; Sandra van Dulmen; Bart van den Bemt; Mart van de Laar Journal: BMC Musculoskelet Disord Date: 2016-10-21 Impact factor: 2.362
Authors: Shahrzad Salmasi; Ayano Kelly; Susan J Bartlett; Maarten de Wit; Lyn March; Allison Tong; Peter Tugwell; Kathleen Tymms; Suzanne Verstappen; Mary A De Vera Journal: BMC Rheumatol Date: 2021-07-08
Authors: Ayano Kelly; Allison Tong; Kathleen Tymms; Lyn March; Jonathan C Craig; Mary De Vera; Vicki Evans; Geraldine Hassett; Karine Toupin-April; Bart van den Bemt; Armando Teixeira-Pinto; Rieke Alten; Susan J Bartlett; Willemina Campbell; Therese Dawson; Michael Gill; Renske Hebing; Alexa Meara; Robby Nieuwlaat; Yomei Shaw; Jasvinder A Singh; Maria Suarez-Almazor; Daniel Sumpton; Peter Wong; Robin Christensen; Dorcas Beaton; Maarten de Wit; Peter Tugwell Journal: Trials Date: 2018-03-27 Impact factor: 2.279